Objective To study the clinical effect and safety of Madopar combined with deep brain stimulation in the treatment of Parkinson's disease. Methods From Mar. 2014 to May 2016, a total of 50 patients with Parkinson's disease in our department were taken as the clinical research objects, and they were randomly divided into observation group (25 cases) and control group (25 cases). Both groups were given conventional treatment of oral Madopar, besides, the observation group accepted additional deep brain stimulation. 1 month after treatment, the Unified Parkinson's Disease Rating Scale score and SCL-90 factor score in the two groups were recorded and analyzed. Results (1)The scores of UPDRS, UPDRSⅠ, UPDRS Ⅱ and UPDRS Ⅲ of the two groups were lower than those of the treatment, and the scores of UPDRS score, UPDRSⅠ, UPDRSⅡ and UPDRSⅢ scores in the observation group were significantly higher than those in the control group,the difference was statistically significant (P <0.05), (2)The scores of SCL-90 were significantly lower in the two groups after treatment than those before treatment,and the observation group were significantly lower than the control group,the difference was significant (P<0.05). Conclusion Compared with single oral Madopar treatment, Madopar combined with deep brain stimulation which has good and definite effect in the treatment of Parkinson's disease, and no obvious adverse reactions, can significantly improve patients' quality of life. Thus, it is worthy of further research and application in clinic.